Azienda Ospedaliera Universitaria (AOU) FEDERICO II di Napoli

Foundation year2018
DirectorProf. Raffaele Dubbioso
Principal investigatorProf. Raffaele Dubbioso

The ALS Center at Federico II University Hospital in Naples, led by Professor Raffaele Dubbioso, is a major referral center in Southern Italy and part of the European ERN network for neuromuscular diseases. The Center manages more than 2,000 neuromuscular patients and follows over 200 people with ALS, with about 60 new cases each year. You receive multidisciplinary care, advanced neurophysiology, neuroimaging, and genetic testing with NGS. The team uses TMS to assess cortical excitability. Research focuses on disease mechanisms and biomarkers, especially confocal skin biopsy. The Center works with the ALS Patients’ Association, the Clinical Investigation Center, and CEINGE to link clinical care with translational research.

Contact Information

AddressNapoliVia Sergio Pansini 580131 Italy

ContactAzienda Ospedaliera Universitaria (AOU) FEDERICO II di Napoli

Phone390817462666
Emailaou.neurofisiologiaclinica@gmail.com

Restricted information

Serving population
12,311,869

Patient resources

Number of skin samples
200
Number of IPS cell samples
15

Banks

TypeALS PatientsControlsOther
DNA bank
Yes
No
Yes
Serum bank
Yes
Yes
Yes
RNA bank
No
No
No

Research Activities

Clinical management research
Neuro epidemiology
Neuro physiology
Neuro imaging
Neuro psychology
Neuro pathology
Genomics
Transcriptomics
Metabolomics

Clinical Trials - Industry Sponsored

ALCALS: A randomized, phase II/III trial on the biological and clinical effects of acetyl-L-carnitine in ALS

Type
Phase II/III randomized, double-blind, placebo- controlled trial
Patients
246 in total, 15 at the center

Clinical Trials - Investigator initiated

ALCALS: A randomized, phase II/III trial on the biological and clinical effects of acetyl-L-carnitine in ALS

Type
Phase II/III randomized, double-blind, placebo- controlled trial
Patients
246 in total, 15 at the center

Publication

  1. Guida N, Valsecchi V, Anzilotti S, Dubbioso R, Cuomo O, Ruggiero S, Senerchia G, Iuzzolino VV, Kolici X, De Iesu N, Pignataro G, Annunziato L, Formisano L. siRNA for REST ameliorates symptoms in ALS mice and serum REST predicts disease prognosis and survival in ALS patients. Mol Ther. 2026 Jan 7;34(1):367-379.
  2. Ranieri F, Senerchia G, Bonan L, Casali S, Cabona C, Cantone M, De Marchi F, Diamanti L, Doretti A, Fini N, Filosto M, Fortuna A, Iovino A, Iuzzolino VV, Lanza G, Lunetta C, Maderna L, Mandrioli J, Mazzini L, Musumeci G, Nuredini A, Sorarù G, Toriello A, Ticozzi N, Todisco M, Vacchiano V, Zinno L, Silani V, Rossi S, Di Lazzaro V, Dubbioso R; MND Study Group of the Italian Neurological Society (SIN) and the Neurostimulation‐Neuromodulation Study Group of the Italian Society of Clinical Neurophysiology (SINC). Cortical Excitability as a Prognostic and Phenotypic Stratification Biomarker in Amyotrophic Lateral Sclerosis. Ann Neurol. 2025 Oct;98(4):801-813. doi: 10.1002/ana.27305.
  3. Spisto M, Moretta P, Senerchia G, Iuzzolino VV, Aruta L, Salvatore E, Santangelo G, Trojano L, Dubbioso R. Identifying Mild Behavioral and Neurocognitive Impairment in Amyotrophic Lateral Sclerosis (MBNI-ALS) Provides Key Prognostic Insights. Eur J Neurol. 2025 May;32(5):e70171. doi: 10.1111/ene.70171.
  4. Dubbioso R, Spisto M, Verde L, Iuzzolino VV, Senerchia G, Salvatore E, De Pietro G, De Falco I, Sannino G. Voice signals database of ALS patients with different dysarthria severity and healthy controls. Sci Data. 2024 Jul 19;11(1):800.
  5. Nolano M, Provitera V, Caporaso G, Fasolino I, Borreca I, Stancanelli A, Iuzzolino VV, Senerchia G, Vitale F, Tozza S, Ruggiero L, Iodice R, Ferrari S, Santoro L, Manganelli F, Dubbioso R. Skin innervation across amyotrophic lateral sclerosis clinical stages: new prognostic biomarkers. Brain. 2024 May 3;147(5):1740-1750.

For other publications, see: https://pubmed.ncbi.nlm.nih.gov/?term=dubbioso